Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)

10.1007/s00280-006-0270-1

Saved in:

Bibliographic Details
Main Authors:	Yeo, W., Zee, B., Ma, B., Lam, K.C., Mo, F.K.F., Ng, E.K.W., Ho, R., Chan, A.T.C., Boyer, M., Clarke, S., Beale, P., Chung, H.C., Roh, J.K., Rha, S.Y., Jeung, H.C., Ong, S.Y.K., Lim, R., Soo, R., Goh, B.C.
Other Authors:	PHARMACOLOGY
Format:	Article
Published:	2011
Subjects:	First line chemotherapy Irofulven Stomach cancer
Online Access:	http://scholarbank.nus.edu.sg/handle/10635/27257
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-27257
record_format	dspace
spelling	sg-nus-scholar.10635-272572024-11-09T00:53:45Z Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG) Yeo, W. Zee, B. Ma, B. Lam, K.C. Mo, F.K.F. Ng, E.K.W. Ho, R. Chan, A.T.C. Yeo, W. Boyer, M. Clarke, S. Beale, P. Chung, H.C. Roh, J.K. Rha, S.Y. Jeung, H.C. Ong, S.Y.K. Lim, R. Soo, R. Goh, B.C. PHARMACOLOGY First line chemotherapy Irofulven Stomach cancer 10.1007/s00280-006-0270-1 Cancer Chemotherapy and Pharmacology 59 3 295-300 2011-09-29T05:54:21Z 2011-09-29T05:54:21Z 2007 Article Yeo, W., Zee, B., Ma, B., Lam, K.C., Mo, F.K.F., Ng, E.K.W., Ho, R., Chan, A.T.C., Yeo, W., Boyer, M., Clarke, S., Beale, P., Chung, H.C., Roh, J.K., Rha, S.Y., Jeung, H.C., Ong, S.Y.K., Lim, R., Soo, R., Goh, B.C. (2007). Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Cancer Chemotherapy and Pharmacology 59 (3) : 295-300. ScholarBank@NUS Repository. https://doi.org/10.1007/s00280-006-0270-1 03445704 http://scholarbank.nus.edu.sg/handle/10635/27257 000243031900002 Scopus
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	First line chemotherapy Irofulven Stomach cancer
spellingShingle	First line chemotherapy Irofulven Stomach cancer Yeo, W. Zee, B. Ma, B. Lam, K.C. Mo, F.K.F. Ng, E.K.W. Ho, R. Chan, A.T.C. Yeo, W. Boyer, M. Clarke, S. Beale, P. Chung, H.C. Roh, J.K. Rha, S.Y. Jeung, H.C. Ong, S.Y.K. Lim, R. Soo, R. Goh, B.C. Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
description	10.1007/s00280-006-0270-1
author2	PHARMACOLOGY
author_facet	PHARMACOLOGY Yeo, W. Zee, B. Ma, B. Lam, K.C. Mo, F.K.F. Ng, E.K.W. Ho, R. Chan, A.T.C. Yeo, W. Boyer, M. Clarke, S. Beale, P. Chung, H.C. Roh, J.K. Rha, S.Y. Jeung, H.C. Ong, S.Y.K. Lim, R. Soo, R. Goh, B.C.
format	Article
author	Yeo, W. Zee, B. Ma, B. Lam, K.C. Mo, F.K.F. Ng, E.K.W. Ho, R. Chan, A.T.C. Yeo, W. Boyer, M. Clarke, S. Beale, P. Chung, H.C. Roh, J.K. Rha, S.Y. Jeung, H.C. Ong, S.Y.K. Lim, R. Soo, R. Goh, B.C.
author_sort	Yeo, W.
title	Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
title_short	Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
title_full	Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
title_fullStr	Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
title_full_unstemmed	Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
title_sort	irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase ii multicenter study by the cancer therapeutics research group (ctrg)
publishDate	2011
url	http://scholarbank.nus.edu.sg/handle/10635/27257
_version_	1821226617931825152

Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)

Similar Items